Movalis efficacy and safety in the treatment of locomotor apparatus diseases
- Authors: Chichasova NV1, Chichasova NV1
-
Affiliations:
- Issue: No 11 (2009)
- Pages: 28-33
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/277297
- ID: 277297
Cite item
Full Text
Abstract
Movalis efficacy and safety in the treatment of locomotor apparatus diseases
Treatment of chronic locomotor diseases is a complex task. Antiinflammatory and analgesic therapy are complicated by advanced age, concomitant diseases and necessity of its treatment. Frequently used classic nonsteroidal antiinflammatory drugs besides positive effects often cause adverse effects from gastrointestinal tract, liver, kidneys, bronchus, what limits the providing of adequate therapy. The cyclo-oxygenase-2 selective inhibitors meloxicam (Movalis) have the same effectiveness as classic nonsteroidal antiinflammatory drugs, but much better tolerability, including elderly people. The paper includes the results of research and clinical practice, confirming the efficiency and safety of Movalis.
Treatment of chronic locomotor diseases is a complex task. Antiinflammatory and analgesic therapy are complicated by advanced age, concomitant diseases and necessity of its treatment. Frequently used classic nonsteroidal antiinflammatory drugs besides positive effects often cause adverse effects from gastrointestinal tract, liver, kidneys, bronchus, what limits the providing of adequate therapy. The cyclo-oxygenase-2 selective inhibitors meloxicam (Movalis) have the same effectiveness as classic nonsteroidal antiinflammatory drugs, but much better tolerability, including elderly people. The paper includes the results of research and clinical practice, confirming the efficiency and safety of Movalis.
References
- Насонов Е.Л. Болевой синдром при патологии опорно-двигательного аппарата // Врач. 2002. № 4. C. 15-19.
- Scott D. Text book of rheumatology. Philadelphia. 1999.
- Чичасова Н.В. Лечение остеоартроза: влияние на хрящевую ткань различных противовоспалительных препаратов // РМЖ. 2005. Т. 13. № 8. C. 539-542.
- Damjanov M. VI International Meeting, Crete, 2008.
- Насонов Е.Л., Лазебник Л.Б., Беленков Ю.Н. и др. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. М., 2006. 88 с.
- Janssen M, Dijkmans B, van der Sluijs FA. Upper gastrointestinal complaints and complication in chronic rheumatic patients in comparison with other chronic diseases. Br J Rheum 1992;31:747-52.
- Henry D, Lim L, Garcia Rodriguez L, et al. Variability in risk of gastrointenstinal complcations with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996;312:1563-66.
- Yocum D, Fleishmann R, Dalgin P, et al. Safety and efficacy of meloxicam in the treatment of osteoarthritis: a 12-week, double-blind, multiple doses, placebo-controlled trial. The Meloxicam Osteoarthritis Investigators. Arch Int Med 2000;160:2947-54.
- Martin RM, Biswas P, Mann RD. The incidence of adverse events and risk factors for upper gastrointestinal disorders associated with meloxicam use amongst 19087 patients in general practice in England: cohort study. Br J Clin Pharmacol 2000;50:35-42.
- Lapisque F, Vergne P, Jouzeau J-I, et al. Articular diffusion of meloxicam after a single oral dose: relationship to cyclo-oxygenase inhibition in synovial cells. Clin Pharmokinet 2000;39:369-82.
- Haskisson EC, Ghozlan R, Kurthen R, et al. A long-term study to evaluate the safety and efficacy of meloxicam therapy in patients with rheumatoid arthritis. Br J Rheum 1996;35(Suppl. 1):29-34.
- Dougados M, Gueguen A, Nakache J-P, et al. Ankylosing spondilitis: what is the optimum duration of a clinical study? A one-year versus 6-weeks nonsteroidal antiinflammatory drug trial. Rheumatology 1999;38:235-44.
- Zeidler H, Kaltwasser JP, Leonard JP, et.al. Prescription and tolerability of meloxicam in day-to-day practice: postmarceting observational cohort study of 13307 patients. J Clin Rheum 2002;8:305-15.
- Singh G, Triadafilopoulos G. Epidemiology of NSAIDs induced gastrointestinal complications. J Rheum 1999;26(Suppl. 56):18-24.
- Winkelmeyer WC, Waikar SS, Mogun H, et al. Nonselective and Cyclooxygenase-2-Selective NSAIDs and acute kidney injury. Am J Med 2008;121:1092-98.
- Davies NM, Skjodt NM. Clinical pharmacokinetics of meloxicam: a cyclo-oxygenase-2 preferential nonsteroidal anti-inflammatory drug. Clin Pharmacokinet 1999;36:115-26.
- Цветкова Е.С. Эффективность и переносимость ступенчатой терапии мовалисом (мелоксикамом) при ревматических заболеваниях // Терапевтический архив. 2004. № 12. C. 78-80.
- Carraba M, Paresce E, et al А comparison of the local tolerability, safety and efficacy of meloxicam and piroxicam suppositories in patients with OA: a single-blind, randomized, multicenter study. Curr Med Res Opin 1995;13(6):343-55.
Supplementary files
